Kohjin Bio (177A) · TargetAdvanced
Development and launch of rapid infectious disease test kits for Asia
First written in FY2024. 2 of 3 entries say "Advanced", first in FY2025. Latest entry: FY2026.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Development and improvement of testing technologies and diagnostic products for POCTA theme 7 companies write about · 1 as a headwind · 11 as a tailwind
4 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「In November 2025, the SARS coronavirus and influenza virus simultaneous-detection antigen test kit KBM Line Check nCoV/Flu II was approved as an in vitro diagnostic product and launched in January 2026.」
The company reports specific progress on rapid infectious disease test kits, including approval and launch of a simultaneous-detection kit. - FY2025AdvancedAnnual report
「In December 2024, the company launched the KBM Line Check NDM NDM-type metallo-β-lactamase detection kit as a research-use reagent for detecting antimicrobial-resistant bacteria.」
The company has launched an NDM detection kit for infectious diseases and antimicrobial-resistant bacteria, for which demand is expected in Asia. - FY2024First statedAnnual report
「The company will generate new revenue by developing and launching rapid test kits for infectious diseases in Asia.」
The company plans to develop and supply test kits targeting demand for infectious disease testing in Asia.